Volume 7, Issue 3 ( Journal of Clinical and Basic Research (JCBR) 2023)
jcbr 2023, 7(3): 12-14 |
Back to browse issues page
Ethics code: IEC/SVS/Path/2018/01
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BV H, Karamchedu S, Fatima R, Nazeer S, . F, D S, et al . A study on molecular subtype of breast carcinoma using ER, HER2, PR, and its relation with Ki67. jcbr 2023; 7 (3) :12-14
URL: http://jcbr.goums.ac.ir/article-1-381-en.html
URL: http://jcbr.goums.ac.ir/article-1-381-en.html
Haricharan BV1 
, Shilpa Karamchedu * 2, Rasheed Fatima1 , Shaik Nazeer1 , Fatima .1 , Sagarika D1 , Suresh K1 , Florence Nightingale1
, Shilpa Karamchedu * 2, Rasheed Fatima1 , Shaik Nazeer1 , Fatima .1 , Sagarika D1 , Suresh K1 , Florence Nightingale1
1- Department of Pathology, SVS Medical College and Hospital, Yenugonda, Mahabubnagar, Telangana-509001, India
2- Department of Pathology, SVS Medical College and Hospital, Yenugonda, Mahabubnagar, Telangana-509001, India ,dr.kshilpa@rediffmail.com
2- Department of Pathology, SVS Medical College and Hospital, Yenugonda, Mahabubnagar, Telangana-509001, India ,
Abstract: (722 Views)
Background: Using molecular biomarkers of breast cancer (BC) receives optimal treatment. Established biomarkers like estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 may play significant roles in the sub-categorization of BC to predict the prognosis and specific therapy for each patient.
This study aims to characterize breast carcinoma using molecular markers (ER, PR, and HER2 neu), identify their sub-types, and attain its relation with Ki67.
Methods: This cross-sectional (retrospective) study was conducted over four years at the Department of Pathology, SVS Medical College, Mahabubnagar, from April 2018 to March 2022. Fifty diagnosed cases of breast carcinomas were subjected to routine staining and immunohistochemistry (IHC) with ER, PR, HER 2 neu, and Ki67 using tissue microarray and classified into molecular subtypes.
Results: In this study, 32% of participants were in the 50-59 age group. The right breast was involved in 52% of participants. The central quadrant was involved in 44%, UOQ 32%, UIQ 16%, and LOQ 8%. Moderately differentiated tumors exist in 40%, poorly differentiated in 36%, and well-differentiated in 24%. 84% of patients were ER-positive, 70% were PR-positive, and 72% were HER2/neu-positive. 28% of patients with positive Ki-67 were grade I, 22% were grade II, and 50% were grade III. Her2/neu contributed to 12% and triple-negative BC seen in 4%. The association between the ER status and Ki-67 positivity status is not statistically significant, with a P-value of 0.13. The association between the PR status and Ki-67 positivity status is statistically significant, with a P-value of 0.002. The association between the Her2/neu status and Ki-67 positivity status is also statistically significant, with a P-value of <0.0001.
Conclusion: Most cases were Ki67 positive and HER2 neu positive. Triple-negative cases showed a high Ki67 index. Ki67 plays a pivotal role in making treatment decisions. The Ki67 index is independent and can be used independently without being correlated with other indices, and Ki67 should be evaluated routinely in breast carcinoma cases.
This study aims to characterize breast carcinoma using molecular markers (ER, PR, and HER2 neu), identify their sub-types, and attain its relation with Ki67.
Methods: This cross-sectional (retrospective) study was conducted over four years at the Department of Pathology, SVS Medical College, Mahabubnagar, from April 2018 to March 2022. Fifty diagnosed cases of breast carcinomas were subjected to routine staining and immunohistochemistry (IHC) with ER, PR, HER 2 neu, and Ki67 using tissue microarray and classified into molecular subtypes.
Results: In this study, 32% of participants were in the 50-59 age group. The right breast was involved in 52% of participants. The central quadrant was involved in 44%, UOQ 32%, UIQ 16%, and LOQ 8%. Moderately differentiated tumors exist in 40%, poorly differentiated in 36%, and well-differentiated in 24%. 84% of patients were ER-positive, 70% were PR-positive, and 72% were HER2/neu-positive. 28% of patients with positive Ki-67 were grade I, 22% were grade II, and 50% were grade III. Her2/neu contributed to 12% and triple-negative BC seen in 4%. The association between the ER status and Ki-67 positivity status is not statistically significant, with a P-value of 0.13. The association between the PR status and Ki-67 positivity status is statistically significant, with a P-value of 0.002. The association between the Her2/neu status and Ki-67 positivity status is also statistically significant, with a P-value of <0.0001.
Conclusion: Most cases were Ki67 positive and HER2 neu positive. Triple-negative cases showed a high Ki67 index. Ki67 plays a pivotal role in making treatment decisions. The Ki67 index is independent and can be used independently without being correlated with other indices, and Ki67 should be evaluated routinely in breast carcinoma cases.
References
1. Rosai J. Rosai and Ackerman's surgical pathology e-book. 10th ed. Edinburgh: Elsevier Health Sciences; 2011. [View at Publisher] [Google Scholar]
2. Lester SC, KV AA. The Breast. Robbins and Cotran Pathologic Basis of Disease, Kumar V, Abbas AK, Aster JC, editors. 10th ed. Elsevier Health Sciences; 2010. p.1065-97. [View at Publisher] [DOI] [Google Scholar]
3. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123(1):21-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Viale G. The current state of breast cancer classification. Ann Oncol. 2012;23:x207-10. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Perou CM, Sørlie T, Eisen MB, Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Setyawati Y, Rahmawati Y, Widodo I, Ghozali A, Purnomosari D. The association between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman. Asian Pac J Cancer Prev. 2018;19(5):1263-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Al-Nuaimi HA, Hamdi E, Mohammed BB. Ki-67 Expression in Breast Cancer, Its Correlation with ER, PR and Other Prognostic Factors in Nineveh Province. Ann Coll Med, Mosul. 2020;42(1):1-0. [View at Publisher] [DOI] [Google Scholar]
8. Mittal A, Mani NS. Molecular classification of breast cancer. Indian J Pathol Oncol 2021;8(2):241-7. [View at Publisher] [DOI] [Google Scholar]
9. Arpita J, Priyanka G, Ranjana S. A Study of Molecular Subtypes of Carcinoma Breast by Immunohistochemistry at Tertiary Care Center, Jaipur. Asian Pac J Cancer Biol.2022;7 (3);219-23. [View at Publisher] [DOI] [Google Scholar]
10. Khanna M, Sharma M, Manjari M, Kaur K, Garg S, Goyal S. Correlation of Ki- 67 with ER, PR, Her2neu and other Prognostic Factors In Breast Carcinoma. Annals of Pathology and Laboratory Medicine. 2016;3(6):540-4. [View at Publisher] [DOI] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).